Cargando…
The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211018/ https://www.ncbi.nlm.nih.gov/pubmed/25337944 http://dx.doi.org/10.3390/ijerph111010991 |
_version_ | 1782341495692460032 |
---|---|
author | Zhang, Haiying Jiao, Ling Cui, Songye Wang, Liang Tan, Jian Zhang, Guizhi He, Yajing Ruan, Shuzhou Fan, Saijun Zhang, Wenyi |
author_facet | Zhang, Haiying Jiao, Ling Cui, Songye Wang, Liang Tan, Jian Zhang, Guizhi He, Yajing Ruan, Shuzhou Fan, Saijun Zhang, Wenyi |
author_sort | Zhang, Haiying |
collection | PubMed |
description | Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients’ external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h(−1) at 1, 1.5, 2 and 3 m, respectively, according to a patient’s released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making. |
format | Online Article Text |
id | pubmed-4211018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-42110182014-10-28 The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma Zhang, Haiying Jiao, Ling Cui, Songye Wang, Liang Tan, Jian Zhang, Guizhi He, Yajing Ruan, Shuzhou Fan, Saijun Zhang, Wenyi Int J Environ Res Public Health Article Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving (131)I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients’ external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h(−1) at 1, 1.5, 2 and 3 m, respectively, according to a patient’s released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making. MDPI 2014-10-21 2014-10 /pmc/articles/PMC4211018/ /pubmed/25337944 http://dx.doi.org/10.3390/ijerph111010991 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Haiying Jiao, Ling Cui, Songye Wang, Liang Tan, Jian Zhang, Guizhi He, Yajing Ruan, Shuzhou Fan, Saijun Zhang, Wenyi The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title | The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title_full | The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title_fullStr | The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title_full_unstemmed | The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title_short | The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma |
title_sort | study of external dose rate and retained body activity of patients receiving (131)i therapy for differentiated thyroid carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211018/ https://www.ncbi.nlm.nih.gov/pubmed/25337944 http://dx.doi.org/10.3390/ijerph111010991 |
work_keys_str_mv | AT zhanghaiying thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT jiaoling thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT cuisongye thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT wangliang thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT tanjian thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT zhangguizhi thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT heyajing thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT ruanshuzhou thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT fansaijun thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT zhangwenyi thestudyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT zhanghaiying studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT jiaoling studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT cuisongye studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT wangliang studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT tanjian studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT zhangguizhi studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT heyajing studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT ruanshuzhou studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT fansaijun studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma AT zhangwenyi studyofexternaldoserateandretainedbodyactivityofpatientsreceiving131itherapyfordifferentiatedthyroidcarcinoma |